Peptide Initiative

Peptide profile · Immune

LL-37

Human cathelicidin-derived antimicrobial peptide (37 amino acids) that disrupts bacterial membranes at MIC 0.62 μM against S. aureus, neutralizes endotoxin (LPS) to prevent septic shock, and has reached Phase II clinical trials as Ropocamptide for wound healing — achieving 6-fold accelerated healing at 0.5 mg/mL in venous leg ulcers

Moderate human trialsResearch compound
Short systemic half-lifeHalf-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes
Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral deliveryBioavailability
4,493.26Molecular weight, Da

Molecular formula

C205H340N60O53

CAS number
154947-66-7
PubChem
16198951
Developed · 1995-1996 (initial identification and characterization); 2014 (Phase I/IIa clinical trial); clinical development ongoing
Gudmundsson, Agerberth and colleagues (characterization, 1995–1996), Karolinska Institute, Sweden; clinical development by Promore Pharma (ropocamptide)

Amino acid sequence

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Wound HealingClinical trials show this peptide heals stubborn wounds six times faster than placebo by boosting new blood vessel growth and tissue repair.

9.4

Fighting InfectionsWorks like a natural antibiotic in your body, punching holes in harmful bacteria including drug-resistant strains that normal antibiotics can't kill .

9.1

Immune BoostCalls your immune cells to action like a chemical alarm, helping your body mount a stronger defense against bacteria, fungi, and viruses .

8.7

Ratings out of 10.

0.5 – 1.6mg

Every documented dose level

PhaseDoseFrequency
4 weeks0.5 mg/mL gelTwice weekly
4 weeks1.6 mg/mL gelTwice weekly
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers & immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas)

Best for

  • Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers

    LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)

    LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Anti-biofilm strategies for chronic wound infections and medical device-associated infections

    LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Boosting innate immune defense in immunocompromised or aging individuals

    LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

Consider alternatives if

Alternative approaches for immune supportConsult your healthcare provider for alternatives to LL-37 based on your specific needs and medical history
Alternative immune-modulating peptidesThymosin Alpha-1LL-37Thymulin
Non-peptide immune supportVitamin D3Zinc supplementationBeta-glucans

Do not use if

  • Known hypersensitivity to cathelicidin peptides or formulation components
  • Active hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity
  • Pregnancy and breastfeeding — insufficient reproductive safety data from clinical trials
  • Severe renal impairment — peptide clearance may be altered

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about LL-37 use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare LL-37 with similar peptides to find the best fit for your goals.

Route

LL-37 is administered Topical application (wound healing)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The LL-37 injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations.

Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses.

At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

LL-37 safety derives from extensive basic research in immunology and dermatology journals (Nature Immunology, Journal of Immunology) demonstrating antimicrobial activity, wound healing promotion, and immune modulation without systemic toxicity.

Human clinical data are limited—most applications remain in vitro or preclinical. Phase 1 safety and pharmacokinetics data suggest good tolerability, but Phase 2+ efficacy trials in infectious disease and skin conditions are ongoing.

The peptide is generally recognized as safe for topical and research applications.


Common side effects · experienced by some users

Local site irritation

Mild redness, warmth, or irritation at the wound application site. This is the most frequently reported adverse effect in clinical trials and reflects the peptide's interaction with wound-bed tissues.

Management
Generally self-limiting. If irritation is significant, reduce application frequency to every other day. Ensure wound is gently cleansed before application.

Transient stinging or burning

Brief stinging or burning sensation upon application to open wound surfaces, typically lasting seconds to minutes.

Management
Allow reconstituted solution to reach room temperature before application. Sensation typically diminishes with subsequent applications as wound healing progresses.

Mild perilesional erythema

Redness in the skin surrounding the treated wound area, reflecting local immune activation and increased blood flow from LL-37-induced angiogenesis.

Management
Usually indicates active healing response. Monitor for signs of infection versus expected inflammatory healing. Should remain localized and non-spreading.

Increased wound exudate

Temporary increase in wound fluid production during initial treatment phase as antimicrobial and pro-healing mechanisms activate.

Management
Use appropriate absorbent wound dressings. Typically normalizes within 1-2 weeks as healing progresses and bacterial bioburden is reduced.

Serious side effects

Hemolytic activity at systemic concentrations

LL-37 demonstrates concentration-dependent hemolysis of human red blood cells at elevated systemic concentrations. This limits parenteral (IV/IM) dosing potential but is not observed with topical wound application at therapeutic doses used in clinical trials.

Management
Topical application avoids systemic hemolysis risk. For any research involving parenteral administration, monitor hemoglobin and hematocrit. Dose-limiting toxicity for systemic routes.

Less commonAllergic contact reaction

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with LL-37
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

LL-37 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeConventional wound dressings (hydrogels, alginates) — LL-37 can be incorporated into wound matrices for sustained delivery and enhanced antimicrobial protection — May be used together under medical guidance.
  • SafeSilver-based antimicrobials — synergistic bactericidal activity through complementary membrane disruption mechanisms — May be used together under medical guidance.
  • SafeGrowth factors (PDGF, EGF) — LL-37 promotes angiogenesis while growth factors drive tissue regeneration for comprehensive wound healing — May be used together under medical guidance.

With medications

  • CautionHigh-concentration saline solutions — elevated salt concentrations can reduce LL-37 antimicrobial activity through charge shielding effects — Use with caution—discuss with your healthcare provider.
  • CautionAnionic surfactants or dressings — may bind and inactivate the cationic LL-37 peptide through electrostatic complexation — Use with caution—discuss with your healthcare provider.
  • CautionSerum-rich wound environments without dose adjustment — serum proteins can partially sequester LL-37 and reduce effective concentration — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside LL-37. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Moderate human trials · first signs days 1-7

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

LL-37 is the active form of cathelicidin, an antimicrobial peptide your immune cells produce to kill bacteria, viruses, and fungi while also reducing inflammation and promoting wound healing.

The deeper mechanism

LL-37 (also known as hCAP-18 C-terminal 37 amino acids) is a 37-amino acid cationic α-helical peptide derived from proteolytic processing of the hCAP18 precursor by neutrophil elastase and cathepsin G.

LL-37 exhibits potent antimicrobial activity through multiple mechanisms: direct membrane disruption via formation of membrane-spanning pores, sequestration of lipopolysaccharides and lipoteichoic acids, intracellular targeting of bacterial nucleic acids, and autophagy induction.

Beyond antimicrobial functions, LL-37 modulates innate and adaptive immunity through TLR9 signaling, promotes chemotaxis of immune cells via formyl peptide receptor-like 1 (FPRL-1/LIPOXIN A4 receptor) activation, enhances angiogenesis and wound healing, and suppresses excessive inflammatory responses through IL-10 upregulation.


What to expect

  1. Days 1-7

    What you might notice

    • Reduction in wound bioburden and bacterial colonization from direct antimicrobial activity
    • Initial wound bed preparation with cleaner, healthier-appearing granulation tissue
    • Possible mild local irritation or stinging upon application that improves with repeated use
    • Early recruitment of immune cells to wound site through FPRL1-mediated chemotaxis

    What's normal

    • The antimicrobial effect begins immediately upon contact with wound bed
    • Increased wound exudate is common during the first week as bacterial killing and immune activation occur
    • Visible wound changes may be subtle initially — the peptide is establishing conditions for healing

    What's next

    • Continue daily application as tolerated
    • Expect wound bed to transition from inflammatory to proliferative phase
    • Take baseline wound measurements and photographs for tracking progress
  2. Week 2-4

    What you might notice

    • Visible wound size reduction and epithelial advancement from wound edges
    • Improved granulation tissue quality with increased vascularity (LL-37-induced angiogenesis)
    • Reduced wound odor and signs of bacterial infection
    • In the Phase I/IIa trial, the 0.5 mg/mL group showed 6-fold accelerated healing at this timepoint

    What's normal

    • Progressive wound contraction and re-epithelialization are expected
    • Some wounds heal faster than others depending on underlying conditions (venous insufficiency, diabetes)
    • Periwound erythema should be stable or decreasing — increasing redness may indicate infection

    What's next

    • Continue treatment until wound closure or per clinical protocol (typically 4-12 weeks)
    • Document weekly wound measurements to track healing trajectory
    • Assess whether to continue current concentration or adjust based on response
  3. Week 4-12

    What you might notice

    • Continued wound closure with re-epithelialization and scar maturation
    • Significant reduction or complete elimination of chronic wound biofilm
    • Wound may reach complete closure during this period for many patients
    • Stable, healthy wound bed without signs of recurrent infection

    What's normal

    • Healing rates vary — some chronic wounds may require the full 12-week course
    • The anti-biofilm effects help prevent the recurrent infections common in chronic wounds
    • Newly healed tissue may appear pink or slightly different from surrounding skin

    What's next

    • Upon wound closure, discontinue LL-37 application
    • Maintain standard wound care and compression therapy if applicable
    • Monitor for wound recurrence at follow-up visits

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to LL-37 over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What is LL-37 and what does the name mean?

LL-37 is the only cathelicidin antimicrobial peptide found in humans. The name derives from its first two amino acids (both Leucine, abbreviated 'L') and its total length of 37 amino acids. It is cleaved from the C-terminus of the 18 kDa precursor protein hCAP-18 (human cationic antimicrobial protein) by proteinase 3 in neutrophils and by kallikreins in skin. Stored in neutrophil specific granules and secreted by epithelial cells, LL-37 is a first-line innate immune defense peptide expressed by the CAMP gene on chromosome 3.

How did LL-37 perform in clinical trials for wound healing?

LL-37 (under the pharmaceutical name Ropocamptide, developed by Promore Pharma in Sweden) completed a Phase I/IIa clinical trial with 34 patients with hard-to-heal venous leg ulcers. The 0.5 mg/mL topical formulation demonstrated a 6-fold greater healing rate compared to placebo over 4 weeks. A larger 148-patient Phase IIb trial has also been completed. The wound healing mechanism involves LL-37's combined antimicrobial, anti-biofilm, angiogenic, and keratinocyte migration-promoting activities.

Why is LL-37 important for fighting antibiotic-resistant bacteria?

Unlike conventional antibiotics that target specific molecular pathways (which bacteria can evolve resistance to), LL-37 kills bacteria through physical membrane disruption — its cationic charge attracts it to anionic bacterial membranes, and its alpha-helical structure creates pores that rapidly lyse the cell. This physical mechanism makes resistance development much more difficult. Additionally, LL-37 disrupts bacterial biofilms, which are the primary reason chronic wound infections resist antibiotic treatment, and it recruits immune cells to clear remaining bacteria.

What is the connection between vitamin D and LL-37?

Vitamin D directly induces the expression of the CAMP gene that encodes hCAP-18 (the LL-37 precursor protein). The vitamin D receptor (VDR) binds to a vitamin D response element in the CAMP promoter, upregulating LL-37 production. This molecular mechanism is a key reason vitamin D supplementation supports immune function — it boosts the body's production of its primary antimicrobial peptide. Vitamin D deficiency is associated with reduced LL-37 levels and increased infection susceptibility.

Why can't LL-37 be used as a systemic antibiotic via IV injection?

LL-37 demonstrates concentration-dependent hemolytic activity — at higher systemic concentrations needed for parenteral antimicrobial therapy, the peptide's membrane-disrupting mechanism also affects human red blood cells. Additionally, serum proteins partially bind and inactivate the peptide, and its half-life in circulation is short due to rapid proteolytic degradation. This is why clinical development has focused on topical wound application, where high local concentrations can be achieved without systemic hemolysis concerns.

How does LL-37 differ from conventional antibiotics in treating wound infections?

LL-37 provides a fundamentally different approach: rather than targeting a single bacterial pathway, it physically disrupts membranes, neutralizes endotoxin, destroys biofilms, recruits immune cells, and simultaneously promotes wound healing through angiogenesis and keratinocyte migration. Conventional antibiotics kill bacteria but do not promote healing, cannot penetrate biofilms effectively, and face resistance evolution. LL-37 addresses all these limitations while remaining effective against antibiotic-resistant strains including MRSA and multi-drug resistant Pseudomonas.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for LL-37, on one page.

LL-37 dosing protocol

Medical disclaimer

LL-37 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

0.5 – 1.6 mg Twice weekly · onset 1-2 weeks
Open the LL-37 calculatorLL-37 calculator